CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

2020 CADTH Symposium Registration is now open

January 27, 2020
Connect with Canadian and international experts in the objective assessment and evaluation of health technologies this April in Toronto, Ontario. We have added an additional full day of thought-provoking and interactive workshops to the program for a total of four days of education, information sharing, and networking. Please note: Anyone can...

Drug Reimbursement Recommendation - glucagon (Baqsimi)

January 24, 2020
Today, CADTH has issued final recommendations for: glucagon (Baqsimi) Indications: Severe hypoglycemic reactions Recommendation: Reimburse with clinical criteria and/or conditions For more information

Drug Reimbursement Recommendation - Trastuzumab Emtansine (Kadcyla) and Cemiplimab (Libtayo)

January 22, 2020
Today, CADTH has issued final recommendations for: Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) Funding Request: For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progressio...

Call for Feedback: Early Identification of Stroke

January 17, 2020
A new project on Early Identification of Stroke is now available for feedback from all interested stakeholders. Early Identification of Stroke Call for Feedback: 2020-01-17 Feedback Due By: 2020-01-31 Consultation Document: Horizon Scanning Report Product Type: Issues in Emerging Health Technologies Submit Feedback

New at CADTH — January 2020

January 10, 2020
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.